Eporatio

Country: European Union

Language: English

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

epoetin theta

Available from:

Ratiopharm GmbH

ATC code:

B03XA01

INN (International Name):

epoetin theta

Therapeutic group:

Other antianemic preparations

Therapeutic area:

Kidney Failure, Chronic; Anemia; Cancer

Therapeutic indications:

Treatment of symptomatic anaemia associated with chronic renal failure in adult patients.Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving chemotherapy.

Product summary:

Revision: 13

Authorization status:

Authorised

Authorization date:

2009-10-29

Patient Information leaflet

                                54
B. PACKAGE LEAFLET
55
PACKAGE LEAFLET: INFORMATION FOR THE USER
EPORATIO 1,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 2,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 3,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 4,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 5,000 IU/0.5 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 10,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 20,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
EPORATIO 30,000 IU/1 ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE
epoetin theta
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor, pharmacist or
nurse.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor, pharmacist or nurse.
This includes any possible
side effects not listed in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Eporatio is and what it is used for
2.
What you need to know before you use Eporatio
3.
How to use Eporatio
4.
Possible side effects
5.
How to store Eporatio
6.
Contents of the pack and other information
7.
Information for injecting yourself
1.
WHAT EPORATIO IS AND WHAT IT IS USED FOR
WHAT EPORATIO IS
Eporatio contains the active substance epoetin theta, which is almost
identical to erythropoietin, a
natural hormone produced by your body. Epoetin theta is a protein
produced by biotechnology. It
works in exactly the same way as erythropoietin. Erythropoietin is
produced in your kidneys and
stimulates your bone marrow to produce red blood cells. Red blood
cells are very important for
distributing oxygen within your body.
WHAT EPORATIO IS USED FOR
Eporatio is used for the treatment of anaemia accompanied by sympt
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 20,000 IU/1 ml solution for injection in pre-filled syringe
Eporatio 30,000 IU/1 ml solution for injection in pre-filled syringe
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Eporatio 1,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 1,000 international units (IU) (8.3
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 2,000 IU (16.7 µg) epoetin theta per
ml.
Eporatio 2,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 2,000 international units (IU) (16.7
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 4,000 IU (33.3 µg) epoetin theta per
ml.
Eporatio 3,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 3,000 international units (IU) (25
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 6,000 IU (50 µg) epoetin theta per ml.
Eporatio 4,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 4,000 international units (IU) (33.3
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 8,000 IU (66.7 µg) epoetin theta per
ml.
Eporatio 5,000 IU/0.5 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 5,000 international units (IU) (41.7
µg) epoetin theta in 0.5 ml solution
for injection corresponding to 10,000 IU (83.3 µg) epoetin theta per
ml.
Eporatio 10,000 IU/1 ml solution for injection in pre-filled syringe
One pre-filled syringe contains 10,000 international
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 27-09-2023
Public Assessment Report Public Assessment Report Bulgarian 16-12-2009
Patient Information leaflet Patient Information leaflet Spanish 27-09-2023
Public Assessment Report Public Assessment Report Spanish 16-12-2009
Patient Information leaflet Patient Information leaflet Czech 27-09-2023
Public Assessment Report Public Assessment Report Czech 16-12-2009
Patient Information leaflet Patient Information leaflet Danish 27-09-2023
Public Assessment Report Public Assessment Report Danish 16-12-2009
Patient Information leaflet Patient Information leaflet German 27-09-2023
Public Assessment Report Public Assessment Report German 16-12-2009
Patient Information leaflet Patient Information leaflet Estonian 27-09-2023
Public Assessment Report Public Assessment Report Estonian 16-12-2009
Patient Information leaflet Patient Information leaflet Greek 27-09-2023
Public Assessment Report Public Assessment Report Greek 16-12-2009
Patient Information leaflet Patient Information leaflet French 27-09-2023
Public Assessment Report Public Assessment Report French 16-12-2009
Patient Information leaflet Patient Information leaflet Italian 27-09-2023
Public Assessment Report Public Assessment Report Italian 16-12-2009
Patient Information leaflet Patient Information leaflet Latvian 27-09-2023
Public Assessment Report Public Assessment Report Latvian 16-12-2009
Patient Information leaflet Patient Information leaflet Lithuanian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 27-09-2023
Public Assessment Report Public Assessment Report Lithuanian 16-12-2009
Patient Information leaflet Patient Information leaflet Hungarian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 27-09-2023
Public Assessment Report Public Assessment Report Hungarian 16-12-2009
Patient Information leaflet Patient Information leaflet Maltese 27-09-2023
Public Assessment Report Public Assessment Report Maltese 16-12-2009
Patient Information leaflet Patient Information leaflet Dutch 27-09-2023
Public Assessment Report Public Assessment Report Dutch 16-12-2009
Patient Information leaflet Patient Information leaflet Polish 27-09-2023
Public Assessment Report Public Assessment Report Polish 16-12-2009
Patient Information leaflet Patient Information leaflet Portuguese 27-09-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 27-09-2023
Public Assessment Report Public Assessment Report Portuguese 16-12-2009
Patient Information leaflet Patient Information leaflet Romanian 27-09-2023
Public Assessment Report Public Assessment Report Romanian 16-12-2009
Patient Information leaflet Patient Information leaflet Slovak 27-09-2023
Public Assessment Report Public Assessment Report Slovak 16-12-2009
Patient Information leaflet Patient Information leaflet Slovenian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Slovenian 27-09-2023
Public Assessment Report Public Assessment Report Slovenian 16-12-2009
Patient Information leaflet Patient Information leaflet Finnish 27-09-2023
Public Assessment Report Public Assessment Report Finnish 16-12-2009
Patient Information leaflet Patient Information leaflet Swedish 27-09-2023
Public Assessment Report Public Assessment Report Swedish 16-12-2009
Patient Information leaflet Patient Information leaflet Norwegian 27-09-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 27-09-2023
Patient Information leaflet Patient Information leaflet Icelandic 27-09-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 27-09-2023
Patient Information leaflet Patient Information leaflet Croatian 27-09-2023

Search alerts related to this product

View documents history